Clinical follow-up studies will have to reevaluate the use of EGFR inhibitors in HCC and restrict it to patients with EGFR expression in liver macrophages, since we would expect a worse outcome in patients where the EGFR is expressed in tumor cells. This evidence concerns the gene EGFR and neoplasm.